Highest-materiality recent filing
Aditxt implements 1-for-27 reverse stock split effective May 18, 2026 for Nasdaq compliance
Reverse split ratio 1-for-27; effective 4:01 p.m. ET May 15; trading on split-adjusted basis from May 18.
Aditxt receives Nasdaq delisting notice for bid price non-compliance; to appeal
Nasdaq Staff Determination on May 6, 2026 for closing bid price below $1 for 30 consecutive business days (March 24–May 5, 2026).
Aditxt shareholders approve reverse stock split authorization up to 1:250
All five director nominees elected; Amro Albanna received 122,066 votes for.
Aditxt issues $1.25M senior notes at 10% due Sept 2026; net proceeds $1M after OID
Note principal $1.25M, purchase price $1M, original issue discount $250K; interest 10% payable monthly.
Aditxt acquisition target Ignite shows $5.7M net loss, going concern doubt
Ignite incurred net loss of $5.7M for 2025; revenue was only $43.5K (down from $72K in 2024).
Aditxt regains Nasdaq compliance following equity restoration to $3.95M
Nasdaq notified Aditxt on April 1, 2026, that it now complies with Listing Rule 5550(b)(1).
Aditxt increases ATM equity offering by $36.8M to up to $53.4M
Maximum aggregate offering price increased by $36.8M to $53,398,964 under existing ATM agreement.
Aditxt acquires Ignite Proteomics for $36M in preferred stock; issues $3.2M notes
Acquired 100% of Ignite Proteomics for 36,000 Series A-2 Convertible Preferred Shares (stated value $36M).
Aditxt announces 1-for-8 reverse stock split effective March 6 for Nasdaq compliance
Reverse split at 1-for-8 ratio, effective 4:01 p.m. ET March 6, 2026; split-adjusted trading begins March 9.
Aditxt shareholders approve name change to bitXbio, Inc. and reverse stock split authorization
Shareholders approved name change to bitXbio, Inc. (455,456 for, 40,462 against).
Aditxt adjourns special meeting to Feb 13 for reverse split, name change, equity plan votes
Special meeting adjourned to Feb 13, 2026 at 12 PM ET to allow more stockholder voting time.
Aditxt gets Nasdaq extension to regain compliance with $2.5M equity rule
Extension granted Jan 27, 2026; must complete financing and file compliance report by May 15, 2026.
Aditxt receives Nasdaq delisting notice for insufficient stockholders' equity
Nasdaq notified Aditxt on Dec 1, 2025, that it fails to meet minimum $2.5M stockholders' equity requirement.
Filed preliminary proxy for special meeting seeking approval of ESPP and non-binding advisory vote on name change to bitXbio, Inc.
Aditxt announces 1-for-113 reverse stock split effective Nov 3, 2025 to regain Nasdaq compliance
Reverse split ratio set at 1-for-113; effective at 4:01 p.m. ET Oct 31, trading begins split-adjusted Nov 3.
Aditxt merger with Evofem terminated after shareholder vote fails, end date passes
Evofem terminated the Merger Agreement effective Oct 20, 2025, citing Section 8.1(b)(ii) (end date passed) and 8.1(b)(iv) (failure to obtain shareholder approval at the special meeting).
Aditxt hires Christopher J. Porcelli as GC, Chief People Officer and Corporate Secretary
Porcelli will receive $350,000 annual base salary and eligibility for senior executive benefit plans.
Aditxt shareholders approve reverse stock split authorization up to 1:250
Reverse split authorization passed: 1,178,583 For, 473,001 Against, 13,596 Abstain.
Aditxt issues $212.5K senior notes at 10% OID, adjourns annual meeting for reverse split vote
Issued senior unsecured notes: $212,500 principal for $170,000 (20% OID), 10% interest, matures Sept 30, 2025.
Aditxt, Evofem amend merger agreement; adds Series G-1 preferred, new closing conditions
Amendment No. 6 adds Evofem Series G-1 Preferred Stock to the definition of Unconverted Company Preferred Stock.
Aditxt files amended 8-K with Evofem unaudited interim financials for H1 2025
Evofem H1 2025 revenue $5.67M, net loss $0.83M (unaudited).
CEO presents Pearsanta IPO plans; commercialization target Q1 2026
CEO Amro Albanna presented at Wall Street Reporter livestream; discussed Pearsanta IPO plans.
Jeffrey Runge not seeking reelection at 2025 Annual Meeting; will serve until term ends.
Aditxt CEO presents autoimmunity unit Adimune; stock at $5M market cap
CEO presented at Wall Street Reporter livestream on July 22, 2025, focusing on subsidiary Adimune.
Aditxt subsidiary Pearsanta targets prostate cancer test launch by end-2025; IPO spin-off planned
Pearsanta plans to launch a lab-developed test for prostate cancer using mitochondrial DNA detection by end of 2025.
CEO Amro Albanna presented at Wall Street Reporter's Next Super Stock livestream on July 8, 2025, discussing business model as 'publicly owned innovation accelerator'.
Aditxt raises $1M in senior notes, invests $925K in Evofem; CEO targets Evofem close by Sept 2025
Issued $1M senior notes (10% interest, maturity Sept 30, 2025) at $800K purchase price (20% original issue discount).
Aditxt receives $190K insider loans from CEO and CInO; issues 600K-share warrant to consultant
CEO Amro Albanna loaned $90,000 and CInO Shahrokh Shabahang loaned $100,000 at 7.5% interest, due July 20, 2025.
Aditxt appoints Evofem CEO Saundra Pelletier to board; officer loans $70K
Board appoints Saundra Pelletier (CEO of Evofem) as director, effective June 5, 2025.
Acquisition of Evofem targeted to close by September 2025; conditions include resolving senior creditor and Evofem shareholder vote.
CEO Amro Albanna lends $233K to Aditxt via unsecured note due Nov 2025
Amro Albanna, CEO, provided $233,000 unsecured loan to Aditxt on May 22, 2025.
Aditxt files amendment with Evofem Q1 results; merger deadline extended to Sep 30, 2025
Evofem Q1 2025 product sales net $845K, down 77% YoY from $3.6M; net income of $956K vs net loss $4.8M.
Aditxt terminates Appili acquisition; eliminates ~$16M closing obligations
Termination of Arrangement Agreement with Appili effective May 31, 2025.
Aditxt Q3 plan: simplify cap table, cut debt, advance Adimune and Pearsanta
CEO states goal is transition from speculative to growth stage by end of Q3 2025.
On June 5, 2025, the Board of Directors (the “ Board ”) of the Company, with the recommendation of the Nominating and Corporate Governance Committee, appointed Ms. Saundra Pelletier as a member of the Board.
Max materiality 0.90 · Median 0.65 · Most common event other_material